Abstract:AimsRearrangement of the platelet‐derived growth factor receptor B (PDGFRB) gene defines a unique group of myeloid/lymphoid neoplasms with frequent eosinophilia and high sensitivity to tyrosine kinase inhibitors. This genetic abnormality is also rarely reported in Philadelphia‐like B‐cell acute lymphoblastic leukaemia/lymphoma (B‐ALL). PDGFRB rearrangement was initially thought to only occur in cases with 5q31–33 rearrangement as determined with conventional cytogenetics; however, there are reported cases with cryptic rearrangements. We aim to develop a broader strategy for screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms.Methods and resultsWe performed fluorescence in‐situ hybridisation (FISH) for PDGFRB rearrangement in 197 patients, including 70 with B‐ALL, 10 with myeloid neoplasms with 5q31–33 rearrangements, and 117 with eosinophilia (≥0.5 × 109/l in peripheral blood or ≥5% in bone marrow), and identified PDGFRB rearrangement in four of 197 (2.0%) cases. In an attempt to identify clinicopathological and genetic features that may have a stronger association with PDGFRB rearrangement, we analysed 13 patients with confirmed PDGFRB rearrangements, including 10 with myeloid neoplasms and three with B‐ALL. Among the 10 patients with myeloid neoplasms, eosinophilia was present in eight, monocytosis in two, 5q31–33 rearrangement in seven, and abnormal bone marrow morphology in all. All patients with myeloid neoplasms showed an excellent response to imatinib, including a patient in blast crisis. The three B‐ALL patients presented de novo, showed no eosinophilia, had a complex karyotype including 5q31–33 rearrangement, and had clinically aggressive courses with ultimate patient demise.ConclusionsThese findings suggest that a higher yield for the identification of PDGFRB rearrangement may result from an index of suspicion in patients with eosinophilia, monocytosis, bone marrow features of a myeloid neoplasm, and 5q31–33 rearrangement, and patients with Philadelphia‐like B‐ALL.

Complete Responses Of Myeloid/Lymphoid Neoplasms With Rearrangement Of Pdgfra Presenting As Aml/All/Myeloid Sarcoma To Imatinib Monotherapy

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

FIP1L1-PDGFRalpha Alone or with Other Genetic Abnormalities Reveals Disease Progression in Chronic Eosinophilic Leukemia but Good Response to Imatinib.

Efficacy and Prognostic Factors of Imatinib Plus Callg2008 Protocol in Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib

A Case of Myeloid Neoplasm with Fip1l1-Pdgfra Rearrangement Without Marked Peripheral Blood Eosinophilia

Myeloid/lymphoid neoplasms with eosinophilia and <i>FLT3</i> rearrangement

Myeloproliferative Neoplasm with FIP1L1-PDGFRA Fusion Presenting as Extramedullary Acute Myeloid Leukemia (Myeloid Sarcoma) in a Lymph

Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Myeloproliferative Neoplasm with FIP 1 L 1-PDGFRA Fusion Presenting as Extramedullary Acute Myeloid Leukemia ( Myeloid Sarcoma ) in a Lymph Node

Systematic Use of Fluorescence In‐situ Hybridisation and Clinicopathological Features in the Screening of PDGFRB Rearrangements of Patients with Myeloid/lymphoid Neoplasms

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement

Myeloid Tumors Accompanying Systemic Mastocytosis, Basophilia, and Abnormal Platelet-Derived Growth Factor Receptor Β

A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement

Myeloid/lymphoid Neoplasm with CEP110-FGFR1 Fusion: an Analysis of 16 Cases Show Common Features and Poor Prognosis.

Eosinophil atypia in a myeloid/lymphoid neoplasm with PDGFRA rearrangement

Myeloid/lymphoid Neoplasms with FLT3 Rearrangement

Successful Treatment of Myeloid Neoplasms Associated with PDGFRA Rearrangement with Imatinib Mesylate

Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

A Case Report of Exceptional Clinical Response to Chemoradiotherapy and Tyrosine Kinase Inhibitors in a Patient with EML4-ALK Fusion Variant 1 Non-Small Cell Lung Cancer